• +1-646-491-9876
    • +91-20-67278686

    Search

    Granulocyte Macrophage Colony Stimulating Factor-Pipeline Review H1 2017

    Granulocyte Macrophage Colony Stimulating Factor-Pipeline Review H1 2017

    • Report Code ID: RW0001834356
    • Category Pharmaceuticals
    • No. of Pages 80
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Pipeline Review, H1 2017

    Summary

    According to the recently published report 'Granulocyte Macrophage Colony Stimulating Factor - Pipeline Review, H1 2017'; Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes.

    Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a glycoprotein secreted by macrophages, T cells, mast cells, NK cells, endothelial cells and fibroblasts. It stimulates the growth and differentiation of hematopoietic precursor cells from various lineages, including granulocytes, macrophages, eosinophils and erythrocytes.

    The report 'Granulocyte Macrophage Colony Stimulating Factor - Pipeline Review, H1 2017' outlays comprehensive information on the Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

    It also reviews key players involved in Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 6, 3 and 2 respectively. Similarly, the universities portfolio in Phase II stages comprises 1 molecule, respectively. Report covers products from therapy areas Oncology, Immunology, Central Nervous System and Respiratory which include indications Rheumatoid Arthritis, Breast Cancer, Melanoma, Solid Tumor, Hepatocellular Carcinoma, Multiple Sclerosis, Muscle Invasive Bladder Cancer (MIBC) , Pancreatic Cancer, Soft Tissue Sarcoma, Bone Cancer, Chronic Obstructive Pulmonary Disease (COPD) , Colon Carcinoma, Juvenile Myelomonocytic Leukemia (JMML) , Leukemias, Liver Cancer, Lung Adenocarcinoma, Lung Disease, Lymphoma, Merkel Cell Carcinoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Liver Cancer, Metastatic Melanoma, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) , Osteoarthritis Pain, Plaque Psoriasis (Psoriasis Vulgaris) , Prostate Cancer, Psoriasis, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Renal Cell Carcinoma and Squamous Cell Carcinoma.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2)
    - The report reviews Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Overview
    Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Companies Involved in Therapeutics Development
    Aduro BioTech Inc
    Amgen Inc
    BriaCell Therapeutics Corp
    Cold Genesys Inc
    GlaxoSmithKline Plc
    Humabs BioMed SA
    KaloBios Pharmaceuticals Inc
    Morphotek Inc
    Sillajen Biotherapeutics
    Takeda Pharmaceutical Company Ltd
    Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Drug Profiles
    CG-0070 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CG0070 + Immune Checkpoint Modulator - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    gimsilumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GSK-3196165 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    lenzilumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibody to Inhibit GM-CSF for Immunological Disorders - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    namilumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    OrienX-010 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pexastimogene devacirepvec - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    STINGVAX - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SVBR-1GM - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    talimogene laherparepvec - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine to Target CD40L and GM-CSF for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Dormant Products
    Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Discontinued Products
    Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Product Development Milestones
    Featured News & Press Releases
    May 15, 2017: Cold Genesys Announces Clinical Results at American Urological Association Annual Meeting 2017
    May 08, 2017: Scottish Medicines Consortium Rejects Imlygic For Use Within NHS Scotland
    May 08, 2017: BriaCell Announces First Patient Dosed in Phase I/IIa Clinical Study of BriaVax in Advanced Breast Cancer
    Apr 25, 2017: Cold Genesys Announces Acceptance of Late Breaking Abstract at American Urological Association (AUA) Annual Meeting 2017
    Apr 24, 2017: SillaJen And Transgene Announce the Enrollment of the First European Patient in Multinational Phase 3 Trial For Pexa-Vec in Advanced Liver Cancer
    Apr 12, 2017: Transgene and Institut Bergonie Start the Phase 2 Part of the METROmaJX Trial
    Mar 15, 2017: BriaCell Receives FDA Clearance to Initiate Phase I/IIa Clinical Trial of BriaVax in Patients with Advanced Breast Cancer
    Mar 07, 2017: BriaCell Files New Patent Application for its Whole-Cell Breast Cancer Vaccine and Companion Diagnostic Platforms
    Feb 06, 2017: BriaCell Moves Forward to Initiate Phase I/IIa Clinical Study for BriaVax in Advanced Breast Cancer
    Dec 05, 2016: BriaCell to Present at a Breast Cancer Symposium, and Enters into a Research Agreement with Terasaki Foundation Laboratory
    Nov 29, 2016: Kalobios To Present At JMML International Symposium
    Nov 29, 2016: BriaCell Files a Patent Application for its Companion Diagnostic Platform to complement BriaVax
    Nov 10, 2016: BriaCell Provides Clinical Development Update on BriaVax
    Oct 26, 2016: BriaCell Announces the Appointment of Biotechnology Veteran William Williams as New CEO and Director
    Oct 06, 2016: Talimogene laherparepvec in melanoma: Added benefit not proven
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Indications, H1 2017
    Number of Products under Development by Indications, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Number of Products under Investigation by Universities/Institutes, H1 2017
    Products under Investigation by Universities/Institutes, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Pipeline by Aduro BioTech Inc, H1 2017
    Pipeline by Amgen Inc, H1 2017
    Pipeline by BriaCell Therapeutics Corp, H1 2017
    Pipeline by Cold Genesys Inc, H1 2017
    Pipeline by GlaxoSmithKline Plc, H1 2017
    Pipeline by Humabs BioMed SA, H1 2017
    Pipeline by KaloBios Pharmaceuticals Inc, H1 2017
    Pipeline by Morphotek Inc, H1 2017
    Pipeline by Sillajen Biotherapeutics, H1 2017
    Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
    Dormant Products, H1 2017
    Dormant Products, H1 2017 (Contd..1) , H1 2017
    Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Top 10 Indications, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Aduro BioTech Inc
    Amgen Inc
    BriaCell Therapeutics Corp
    Cold Genesys Inc
    GlaxoSmithKline Plc
    Humabs BioMed SA
    KaloBios Pharmaceuticals Inc
    Morphotek Inc
    Sillajen Biotherapeutics
    Takeda Pharmaceutical Company Ltd

    Request for Sample

    Report Url https://www.reportsweb.com//granulocyte-macrophage-colony-stimulating-factor-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//granulocyte-macrophage-colony-stimulating-factor-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//granulocyte-macrophage-colony-stimulating-factor-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments